Zacks: Analysts Anticipate TG Therapeutics Inc (TGTX) to Post -$0.47 EPS

Equities research analysts expect TG Therapeutics Inc (NASDAQ:TGTX) to announce earnings of ($0.47) per share for the current fiscal quarter, Zacks Investment Research reports. Three analysts have provided estimates for TG Therapeutics’ earnings, with estimates ranging from ($0.49) to ($0.45). TG Therapeutics posted earnings per share of ($0.59) in the same quarter last year, which suggests a positive year over year growth rate of 20.3%. The company is scheduled to announce its next quarterly earnings report on Tuesday, May 14th.

On average, analysts expect that TG Therapeutics will report full year earnings of ($1.63) per share for the current year, with EPS estimates ranging from ($1.91) to ($1.15). For the next year, analysts anticipate that the company will post earnings of ($1.39) per share, with EPS estimates ranging from ($1.71) to ($0.84). Zacks’ EPS averages are a mean average based on a survey of analysts that that provide coverage for TG Therapeutics.

TGTX has been the topic of a number of research analyst reports. HC Wainwright restated a “buy” rating on shares of TG Therapeutics in a research report on Tuesday, January 22nd. Jefferies Financial Group restated a “buy” rating and issued a $8.00 target price on shares of TG Therapeutics in a research report on Wednesday, February 6th. B. Riley assumed coverage on TG Therapeutics in a report on Tuesday, January 8th. They issued a “buy” rating and a $10.00 price objective on the stock. BidaskClub upgraded TG Therapeutics from a “strong sell” rating to a “sell” rating in a report on Wednesday, January 2nd. Finally, Cantor Fitzgerald assumed coverage on TG Therapeutics in a report on Friday, March 29th. They issued an “overweight” rating and a $17.00 price objective on the stock. Two research analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. TG Therapeutics presently has an average rating of “Buy” and a consensus price target of $14.07.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in TGTX. JPMorgan Chase & Co. lifted its holdings in shares of TG Therapeutics by 7.0% in the third quarter. JPMorgan Chase & Co. now owns 304,497 shares of the biopharmaceutical company’s stock worth $1,705,000 after buying an additional 19,957 shares in the last quarter. Alliancebernstein L.P. lifted its holdings in shares of TG Therapeutics by 31.8% in the third quarter. Alliancebernstein L.P. now owns 82,540 shares of the biopharmaceutical company’s stock worth $462,000 after buying an additional 19,900 shares in the last quarter. Bank of New York Mellon Corp lifted its holdings in shares of TG Therapeutics by 3.8% in the third quarter. Bank of New York Mellon Corp now owns 286,843 shares of the biopharmaceutical company’s stock worth $1,606,000 after buying an additional 10,518 shares in the last quarter. BlackRock Inc. lifted its holdings in shares of TG Therapeutics by 8.3% in the third quarter. BlackRock Inc. now owns 4,420,852 shares of the biopharmaceutical company’s stock worth $24,757,000 after buying an additional 339,802 shares in the last quarter. Finally, Dimensional Fund Advisors LP purchased a new stake in shares of TG Therapeutics in the third quarter worth about $361,000. 55.53% of the stock is owned by hedge funds and other institutional investors.

NASDAQ:TGTX opened at $8.09 on Tuesday. TG Therapeutics has a 52 week low of $3.32 and a 52 week high of $16.00. The firm has a market capitalization of $711.69 million, a price-to-earnings ratio of -4.24 and a beta of 2.31.

About TG Therapeutics

TG Therapeutics, Inc, a biopharmaceutical company, engages in developing and delivering medicines for patients with chronic lymphocytic leukemia (CLL), non-Hodgkin's Lymphoma (NHL), and Multiple Sclerosis (MS). It develops a robust B-cell directed research and development platform for identification of key B-cell pathways of interest and rapid clinical testing.

Further Reading: What is Net Asset Value (NAV)?

Get a free copy of the Zacks research report on TG Therapeutics (TGTX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for TG Therapeutics (NASDAQ:TGTX)

Receive News & Ratings for TG Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TG Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.